Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902718 | 0.86 | CDC7 (0.42) | CDC7MAPTMAP4K4IRAK4MKNK1 | |
| SCHEMBL1896821 | 0.85 | CDC7 (0.58) | CDC7MAPTMAP4K4IRAK4CDK2 | |
| SCHEMBL13556184 | 0.83 | MAPT (0.43) | CDC7MAPTMKNK1MKNK2KDR | |
| SCHEMBL13556113 | 0.83 | CDC7 (0.43) | CDC7MAPTMKNK1MKNK2KDR | |
| SCHEMBL1897525 | 0.81 | CDC7 (0.45) | CDC7MAPTMKNK1MKNK2 | |
| SCHEMBL1894817 | 0.79 | MKNK1 (0.47) | MKNK1MKNK2KDR | |
| SCHEMBL1896942 | 0.76 | CDC7 (0.62) | CDC7CDK2 | |
| SCHEMBL1226114 | 0.75 | KIT (0.46) | MAPTMAP4K4KDR | |
| SCHEMBL1224813 | 0.75 | KIT (0.43) | MAP4K4KDR | |
| SCHEMBL1901272 | 0.73 | MAPT (0.46) | MAPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765749-B2 | 1,6-disubstituted indole compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-01 | — | — | US | disclosed |
| US-8765749-B2 | 1,6-disubstituted indole compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-01 | — | — | US | disclosed |
| US-8765749-B2 | 1,6-disubstituted indole compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-01 | — | — | US | disclosed |
| US-20120271048-A1 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120271048-A1 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120271048-A1 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-25 | — | — | US | disclosed |
| WO-2011052923-A2 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011052923-A2 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271048-A1 | NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K6, MAP3K20, MAP3K1 | CDC7 275/4885MAPT 2269/4885MAP4K4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.